Lipocine Inc.

LPCN

$43M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaSALT LAKE CITY

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Placebo Phase 3 Results Expected

April 2026~LPCN 1144 Formulation A80

Primary completion for Placebo trial (NCT06979544) in Depression, Postpartum

Source

⭐Phase 3

LPCN 1154A Phase 3 Results Expected

April 2026~LPCN 1154A80

Primary completion for LPCN 1154A trial (NCT06979544) in Depression, Postpartum

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

LPCN 1154A

Phase 3

Depression, Postpartum

Oral testosterone undecanoate, LPCN 1021

Phase 3

Male Hypogonadism

LPCN 1021

Phase 3

Hypogonadism, Male

LPCN 1144 Formulation A

Phase 2

Nonalcoholic Steatohepatitis (NASH)

LPCN 1144

Phase 2

NASH - Nonalcoholic Steatohepatitis

LPCN 1148

Phase 2

Liver Cirrhosis

Drug Name	Phase	Indication	Designations
LPCN 1154A	Phase 3	Depression, Postpartum	-
Oral testosterone undecanoate, LPCN 1021	Phase 3	Male Hypogonadism	-
LPCN 1021	Phase 3	Hypogonadism, Male	-
LPCN 1144 Formulation A	Phase 2	Nonalcoholic Steatohepatitis (NASH)	-
LPCN 1144	Phase 2	NASH - Nonalcoholic Steatohepatitis	-
LPCN 1148	Phase 2	Liver Cirrhosis	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

LPCN News